Metabolic & obesity · Phase III

Top sponsors

• Takeda 35 programs
• NovoThirteen 25 programs
• Eli Lilly and 20 programs
• Regeneron UK 12 programs
• Boehringer Ingelheim 10 programs
• Novo Nordisk A/S 10 programs
• AstraZeneca 9 programs
• LEXICON PHARMACEUTICALS 8 programs
• Eli Lilly and 6 programs
• HOFFMANN-LA ROCHE 6 programs
• George Institute for 5 programs
• Kailera Therapeutics 5 programs

1. Duloxetine hydrochloride

   Eli Lilly and Company

   Diabetic Neuropathies

   phase 3 · small molecule · completed

   1 trial →

2. Eloralintide

   Eli Lilly and Company

   Obesity

   phase 3 · small molecule · active

   1 trial →

3. Empagliflozin 10 MG

   Hospital Authority, Hong Kong

   Diabetic Nephropathies

   phase 3 · small molecule · terminated

   1 trial →

4. Empagliflozin 20 mg

   COLLEGIUM PHARMACEUTICAL, INC

   Metabolic Syndrome

   phase 3 · small molecule · active

   1 trial →

5. Faricimab

   Hoffmann-La Roche

   Diabetic Macular Edema

   phase 3 · small molecule · completed

   1 trial →

6. Fasiglifam (TAK-875)

   Takeda

   Diabetes Mellitus, Type 2

   phase 3 · small molecule · terminated

   1 trial →

7. Faster-acting insulin aspart

   Novo Nordisk A/S

   Diabetes

   phase 3 · small molecule · completed

   1 trial →

8. Finerenone (BAY94-8862)

   Bayer HealthCare AG

   Diabetic Kidney Disease

   phase 3 · small molecule · completed

   1 trial →

9. Glargine

   Eli Lilly and Company

   Diabetes Mellitus, Type 2

   phase 3 · small molecule · completed

   1 trial →

10. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

11. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 · small molecule · completed

    1 trial →

12. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

13. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

14. I4V-MC-JAJJ

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 · small molecule · active

    1 trial →

15. I6T-MC-AMCD

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 · small molecule · active

    1 trial →

16. I6T-MC-AMCE

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 · small molecule · active

    1 trial →

17. I8F-MC-GPGN

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · active

    1 trial →

18. I8F-MC-GPHP

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 · small molecule · active

    1 trial →

19. I8F-MC-GPIX

    Eli Lilly Co.

    Obesity

    phase 3 · small molecule · active

    1 trial →

20. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

21. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 · small molecule · completed

    1 trial →

22. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 · small molecule · completed

    1 trial →

23. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 · small molecule · completed

    1 trial →

24. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 · small molecule · completed

    1 trial →

25. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 · small molecule · completed

    1 trial →

26. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 · small molecule · completed

    1 trial →

27. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 · small molecule · completed

    1 trial →

28. J1I-MC-GZBO

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 · small molecule · active

    1 trial →

29. J1I-MC-GZBP

    Eli Lilly Co.

    Obesity

    phase 3 · small molecule · active

    1 trial →

30. J1I-MC-GZQD

    Eli Lilly Co.

    Overweight, Chronic Low Back Pain (CLBP), Obesity

    phase 3 · small molecule · active

    1 trial →

31. J2A-MC-GZGW

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

32. J2A-MC-GZPO

    Eli Lilly Co.

    GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

    phase 3 · small molecule · active

    1 trial →

33. J3R-MC-YDAF

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 · small molecule · active

    1 trial →

34. J3R-MC-YDAG

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 · small molecule · active

    1 trial →

35. J3R-MC-YDAL

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 · small molecule · active

    1 trial →

36. J3R-MC-YDAO

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 · small molecule · active

    1 trial →

37. K9531-3103

    Kailera Therapeutics

    Obesity

    phase 3 · small molecule · active

    1 trial →

38. K9531-3104

    Kailera Therapeutics

    Obesity

    phase 3 · small molecule · active

    1 trial →

39. K9531-3107

    Kailera Therapeutics

    Obesity

    phase 3 · small molecule · active

    1 trial →

40. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 · small molecule · active

    3 trials →

41. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 · small molecule · active

    1 trial →

42. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 · other · completed

    1 trial →

43. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

44. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    1 trial →

45. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 · small molecule · completed

    1 trial →

46. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 · other · completed

    1 trial →

47. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 · small molecule · completed

    3 trials →

48. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 · small molecule · active

    1 trial →

Frequently asked questions